Join
Live feed
·
PRReleasevia Quantisnow
Apellis Pharmaceuticals Inc. logo
Biogen Inc. logo

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APLS (Apellis Pharmaceuticals Inc.), BIIB (Biogen Inc.) and more on Quantisnow.